Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: BEIGF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BeOne Medicines Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BeOne Medicines Ltd.'s regulatory disclosures and financial reporting.
Baker Bros. Advisors and related entities report beneficial ownership of approximately 115.9 million Ordinary Shares, representing 8.0% of the Ordinary Shares of the issuer, primarily through American Depositary Shares. The ownership is held across Baker Bros. funds and affiliated entities, with the adviser exercising voting and investment power.
On June 11, 2026, Felix J. Baker, Ph.D. was elected to the issuer’s board of directors as Lead Director, while prior directors and adviser employees Michael Goller and Ranjeev Krishana did not stand for re‑election and left the board. In connection with his election, Felix Baker received 18,980 restricted share units that vest into Ordinary Shares, subject to continued board service. The filing also details option and RSU holdings and clarifies that compensation received by adviser employees serving as directors is for the economic benefit of the Baker funds.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported a compensation-related equity grant linked to its board. On June 11, 2026, the company granted 18,980 restricted share units payable solely in ordinary shares to Felix J. Baker in connection with his election to the board under the 2016 Share Option and Incentive Plan. The RSUs vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service. Due to the Baker Bros. fund structure, the RSU grant and resulting ordinary shares are reflected as indirect proportionate pecuniary interests of affiliated funds, with investment adviser Baker Bros. Advisors LP holding voting and dispositive power. The filing also notes indirect and direct holdings of American Depositary Shares, with each ADS representing 13 ordinary shares.
ONC affiliate filed a Section 144 notice to sell 945 ADS. The filing states the ADS arise from restricted stock vesting under a registered plan and lists a planned cash sale with an anticipated sale date of 05/26/2026.
The filing also reports that 212 ADS were sold on 05/22/2026 for $65,632.97. The form bears a filing reference date of 06/15/2026.
ONC filing a Form 144 notifies the proposed sale of 1,484 ADS on 06/08/2026 for $399,738.11. The filing also lists 626 ADS tied to restricted stock vesting under a registered plan with a 06/10/2026 date.
Issuer filed a notice under Rule 144 to sell ADSs. The filing lists 756 ADS to be sold in connection with restricted stock vesting under a registered plan with an effective date of 06/10/2026. The excerpt also reports 1,367 ADS sold on 06/08/2026.
The issuer filed a Form 144 notice related to 631 ADS tied to restricted stock vesting under a registered plan with a vesting date of 06/10/2026 and a filing date of 06/11/2026. The notice lists Morgan Stanley Smith Barney LLC as the broker-dealer.
ONC submitted a Rule 144 notice regarding proposed sales of American Depositary Shares (ADS). The filing lists an ADS quantity 43,466.56, an identifier 54,885,669, and dates including 06/10/2026 and 06/11/2026. The filer named is Titus Benjamin Ball.
ONC: proposed disposition of American Depositary Shares reported on Form 144. The filing names Chan Lee and shows a proposed sale of 428 ADS on 06/10/2026 related to Restricted Stock Vesting Under a Registered Plan. The notice also lists recent sales: 871 ADS on 06/08/2026 for $235,539.13, 332 ADS on 05/13/2026 for $103,159.04, 332 ADS on 04/08/2026 for $103,447.88, and 341 ADS on 03/11/2026 for $102,300.00.
ONC filing a Form 144 reporting a proposed sale of 4,940 ADS by John Oyler on 06/08/2026. The excerpt shows the ADS relate to restricted stock vesting under a registered plan with a vesting date of 06/10/2026. The broker listed is Morgan Stanley Smith Barney LLC at 1 New York Plaza, New York.
BeOne Medicines Ltd. held its 2026 annual general meeting, where shareholders approved all 20 proposals, including financial statements, director elections and compensation items under Swiss law.
Investors approved the Fifth Amended and Restated 2016 Share Option and Incentive Plan, increasing the shares available for awards by 75,400,000 ordinary shares, and the Sixth Amended and Restated 2018 Employee Share Purchase Plan, adding a further 3,250,000 ordinary shares for employee purchases. Shareholders re-elected John V. Oyler as chairman, refreshed the board and compensation committee, and ratified Ernst & Young entities as auditors.
They also granted a general mandate allowing the board to issue up to 20% of issued shares and a separate mandate to repurchase up to 10% of ordinary shares (excluding certain categories). A Connected Person Placing Authorization was approved, permitting allocations to Amgen Inc. to maintain its ownership percentage in future offerings.